Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.74 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.61 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | NCF1 | P14598 | 1/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4429235 | 0.98 | HRH3 (0.78) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL2265992 | 0.98 | HRH3 (0.78) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL1334239 | 0.96 | HRH3 (0.75) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL11201497 | 0.88 | HRH3 (0.94) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL3241388 | 0.86 | HRH3 (0.74) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL3240187 | 0.86 | HRH3 (0.66) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| Hydrochloric Acid SCHEMBL11196296 | 0.85 | HRH3 (0.90) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL4277270 | 0.85 | HRH3 (1.00) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL4764364 | 0.84 | HRH3 (0.78) | HRH3HRH4ALDH1A1KDM4EMBTD1 | |
| SCHEMBL3242385 | 0.84 | HRH3 (0.68) | HRH3HRH4ALDH1A1KDM4ECYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | claimed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | claimed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | claimed |
| JP-2012500783-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-2331518-A1 | NEW BRADYKININ B1 ANTAGONISTS | Evotec AG (DE) | 2011-06-15 | — | — | EP | claimed |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| CN-107074860-B | Methods for preparing TOLL-like receptor modulators | 吉利德科学公司 | 2022-07-15 | — | — | CN | disclosed |
| CN-113454086-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-113423708-A | Imidazo [2,1-F ] [1,2,4] triazin-4-amine derivatives as TLR7 agonists | 百济神州有限公司 | 2021-09-21 | — | — | CN | disclosed |
| EP-3578562-B1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | ANACOR PHARMACEUTICALS INC (US) | 2021-06-23 | — | — | EP | disclosed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-10882872-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10562921-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3578562-A1 | L-VALINATE AMIDE BENZOXABOROLE DERIVATIVES FOR THE TREATMENT OF PARASITIC DISEASES | Anacor Pharmaceuticals, Inc (US) | 2019-12-11 | — | — | EP | disclosed |
| EP-3455227-A1 | OXABOROLE ESTERS AND USES THEREOF | Anacor Pharmaceuticals, Inc (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | US | disclosed |
| WO-2017195069-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885HRH4 2771/4885ALDH1A1 585/4885 |
| US-10882872-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885HRH4 2771/4885ALDH1A1 585/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885HRH4 2771/4885ALDH1A1 585/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885HRH4 2771/4885ALDH1A1 585/4885 |
| US-20170327519-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885HRH4 2771/4885ALDH1A1 585/4885 |
| US-10562921-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | HRH3 2501/4885HRH4 2771/4885ALDH1A1 585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.